{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:03:04Z","timestamp":1769601784931,"version":"3.49.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T00:00:00Z","timestamp":1466035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Breast Cancer Now with support from the Mary-Jean Mitchell Green Foundation"},{"name":"Breast Cancer Now with support from the Mary-Jean Mitchell Green Foundation"},{"name":"National Health Service funding to the NIHR Biomedical Research Centre at The Royal Marsden and the Institute of Cancer Research"},{"name":"National Health Service funding to the NIHR Biomedical Research Centre at The Royal Marsden and the Institute of Cancer Research"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0157397","type":"journal-article","created":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T19:30:33Z","timestamp":1466105433000},"page":"e0157397","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation"],"prefix":"10.1371","volume":"11","author":[{"given":"Stephanie K.","family":"Guest","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Pancholi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Nikitorowicz-Buniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikiana","family":"Simigdala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitch","family":"Dowsett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen R.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley-Ann","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,6,16]]},"reference":[{"issue":"9","key":"ref1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrc2713","article-title":"Biological determinants of endocrine resistance in breast cancer","volume":"9","author":"EA Musgrove","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrc721","article-title":"Endocrine-responsive breast cancer and strategies for combating resistance","volume":"2","author":"S Ali","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/bcr3191","article-title":"Preclinical and clinical studies of estrogen deprivation support the PDGF\/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer","volume":"14","author":"MT Weigel","year":"2012","journal-title":"Breast Cancer Res"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10549-010-1312-2","article-title":"Significance of ER-Src axis in hormonal therapy resistance","volume":"130","author":"S Vallabhaneni","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.tem.2005.06.010","article-title":"Estrogen rapid action via protein complex formation involving ERalpha and Src","volume":"16","author":"RX Song","year":"2005","journal-title":"Trends Endocrinol Metab"},{"issue":"9\u201310","key":"ref6","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.steroids.2007.12.028","article-title":"MNAR plays an important role in ERa activation of Src\/MAPK and PI3K\/Akt signaling pathways","volume":"73","author":"BJ Cheskis","year":"2008","journal-title":"Steroids"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-005-9120-9","article-title":"Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells","volume":"97","author":"S Hiscox","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1158\/0008-5472.CAN-06-1020","article-title":"Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells","volume":"67","author":"P Fan","year":"2007","journal-title":"Cancer research"},{"issue":"27","key":"ref9","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"LJ Lombardo","year":"2004","journal-title":"J Med Chem"},{"issue":"21","key":"ref10","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-11-0070","article-title":"A phase 2 trial of dasatinib in patients with advanced HER2-positive and\/or hormone receptor-positive breast cancer","volume":"17","author":"EL Mayer","year":"2011","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"21","key":"ref11","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1158\/1078-0432.CCR-11-0288","article-title":"Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study","volume":"17","author":"RS Finn","year":"2011","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"18","key":"ref12","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1158\/1078-0432.CCR-11-1071","article-title":"Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing","volume":"17","author":"CI Herold","year":"2011","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1158\/2159-8290.CD-NB2013-181","article-title":"Dasatinib-letrozole gets split verdict","volume":"4","year":"2014","journal-title":"Cancer Discov"},{"issue":"33","key":"ref14","doi-asserted-by":"crossref","first-page":"30458","DOI":"10.1074\/jbc.M305226200","article-title":"Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation","volume":"278","author":"LA Martin","year":"2003","journal-title":"J Biol Chem"},{"issue":"6","key":"ref15","first-page":"1587","article-title":"Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7\/TAMR-1","volume":"54","author":"AE Lykkesfeldt","year":"1994","journal-title":"Cancer research"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1677\/erc.1.01123","article-title":"Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression","volume":"13","author":"N Sarwar","year":"2006","journal-title":"Endocrine-related cancer"},{"issue":"13","key":"ref17","first-page":"4961","article-title":"Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors","volume":"9","author":"J Beliakoff","year":"2003","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/1476-4598-9-278","article-title":"Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET\/PTC1-expressing cell line","volume":"9","author":"D Caccia","year":"2010","journal-title":"Molecular cancer"},{"issue":"19 Pt 1","key":"ref19","doi-asserted-by":"crossref","first-page":"6924","DOI":"10.1158\/1078-0432.CCR-05-0757","article-title":"Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells","volume":"11","author":"FM Johnson","year":"2005","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1158\/1535-7163.MCT-09-0151","article-title":"Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin","volume":"8","author":"P Ceppi","year":"2009","journal-title":"Molecular cancer therapeutics"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1677\/ERC-07-0240","article-title":"ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2","volume":"15","author":"S Pancholi","year":"2008","journal-title":"Endocrine-related cancer"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10549-006-9463-x","article-title":"Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type\/"triple-negative" breast cancer cell lines growing in vitro","volume":"105","author":"RS Finn","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1093\/annonc\/mdq757","article-title":"Src: a potential target for the treatment of triple-negative breast cancer","volume":"22","author":"D Tryfonopoulos","year":"2011","journal-title":"Ann Oncol"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/0008-5472.CAN-06-3633","article-title":"Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection","volume":"67","author":"F Huang","year":"2007","journal-title":"Cancer research"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.bjc.6605381","article-title":"Activity of the multikinase inhibitor dasatinib against ovarian cancer cells","volume":"101","author":"GE Konecny","year":"2009","journal-title":"Br J Cancer"},{"issue":"11","key":"ref26","doi-asserted-by":"crossref","first-page":"R255","DOI":"10.1186\/gb-2007-8-11-r255","article-title":"Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring","volume":"8","author":"XD Wang","year":"2007","journal-title":"Genome Biol"},{"issue":"14","key":"ref27","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1158\/0008-5472.CAN-05-3952","article-title":"Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b","volume":"66","author":"RB Riggins","year":"2006","journal-title":"Cancer research"},{"issue":"7074","key":"ref28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature04296","article-title":"Oncogenic pathway signatures in human cancers as a guide to targeted therapies","volume":"439","author":"AH Bild","year":"2006","journal-title":"Nature"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1158\/1535-7163.MCT-09-1117","article-title":"Development of candidate genomic markers to select breast cancer patients for dasatinib therapy","volume":"9","author":"S Moulder","year":"2010","journal-title":"Molecular cancer therapeutics"},{"issue":"20","key":"ref30","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1158\/1078-0432.CCR-14-0800","article-title":"Gene signature-guided dasatinib therapy in metastatic breast cancer","volume":"20","author":"L Pusztai","year":"2014","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"7347","key":"ref31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature10098","article-title":"Global quantification of mammalian gene expression control","volume":"473","author":"B Schwanhausser","year":"2011","journal-title":"Nature"},{"issue":"24 Supplement","key":"ref32","first-page":"PD01","article-title":"PD01-01: Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor","volume":"71","author":"G Wright","year":"2012","journal-title":"Cancer research"},{"issue":"24 Supplement","key":"ref33","article-title":"PD01-02: Randomized Phase II Study of Dasatinib vs Placebo in Addition to Exemestane in Advanced ER\/PR-Positive Breast Cancer [BMS CA180-261 Study]","volume":"71","author":"A Llombart","year":"2012","journal-title":"Cancer research"},{"issue":"24 Supplement","key":"ref34","article-title":"Abstract S3-07: Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy","volume":"73","author":"D Paul","year":"2014","journal-title":"Cancer research"},{"issue":"7","key":"ref35","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/onc.2011.288","article-title":"The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk","volume":"31","author":"E Arpaia","year":"2012","journal-title":"Oncogene"},{"issue":"9","key":"ref36","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cellsig.2012.05.011","article-title":"A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen","volume":"24","author":"BM Eastman","year":"2012","journal-title":"Cell Signal"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-011-1751-4","article-title":"The role of caveolin-1 in human breast cancer","volume":"131","author":"N Patani","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10549-009-0355-8","article-title":"Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance","volume":"119","author":"NB Thomas","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"46","key":"ref39","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1038\/onc.2011.642","article-title":"Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells","volume":"31","author":"G Castoria","year":"2012","journal-title":"Oncogene"},{"issue":"9","key":"ref40","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1210\/me.2012-1140","article-title":"ERalpha phosphorylation at Y537 by Src triggers E6-AP-ERalpha binding, ERalpha ubiquitylation, promoter occupancy, and target gene expression","volume":"26","author":"J Sun","year":"2012","journal-title":"Mol Endocrinol"},{"issue":"1\u20132","key":"ref41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2008.04.019","article-title":"PELP1\u2014a novel estrogen receptor-interacting protein","volume":"290","author":"DW Brann","year":"2008","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"ref42","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/iub.287","article-title":"PELP1: A novel therapeutic target for hormonal cancers","volume":"62","author":"D Chakravarty","year":"2010","journal-title":"IUBMB Life"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0157397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T13:11:28Z","timestamp":1540041088000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0157397"}},"subtitle":[],"editor":[{"given":"Antimo","family":"Migliaccio","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,6,16]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,6,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0157397","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,16]]}}}